Areas of Expertise


The two main types are Hodgkin lymphoma and the more common non-Hodgkin lymphoma. Non-Hodgkin lymphoma can be indolent where treatment may not always be needed or aggressive, where tumor cells multiply and spread more rapidly, causing  the patient to become very sick.  In recent years, the prognosis of many sub-types of lymphoma has improved tremendously due to the introduction of novel targeted drugs and immunotherapy.

Multiple Myeloma

Multiple myeloma is a cancer of the bone marrow plasma cells. Unlike many cancers, multiple myeloma does not exist as a lump or tumour. It is confirmed by the demonstration of increased plasma cells in the bone marrow and a monoclonal protein band when the patients present with bone problems, kidney failure, high calcium levels or anaemia. Early treatment can be effective at controlling the disease, relieving its complications, and prolonging life. Standard treatment for multiple myeloma is evolving rapidly with the introduction of novel drugs and immunotherapy.

Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It's a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Many patients do not have any symptoms for at least a few years. But over time, the cells grow in number and spread to other parts of the body, including the lymph nodes, liver, and spleen. Blood tests can be done for early detection.  With advances in treatment, a chemo-free approach to CLL is now a reality.

About Dr. Daryl Tan - Specialist in Blood Disorders

Dr Daryl Tan 1000x1000

Dr Daryl Tan is a haematologist who was awarded the Singapore Government Human Manpower Development Plan (HMDP) fellowship to pursue postdoctoral training and clinical research in the field of lymphoma at Stanford University, USA. He is currently a board member of the Chapter of Haematologists and is appointed by the Ministry of Health as an advisor for the Residency Advisory Committee for Haematology training in Singapore. In 2011 Dr Tan helped set up a comprehensive haematology service and became the managing partner of the Raffles Cancer Centre and the Director of Research of Raffles Hospital. He integrated research with clinical practice, availing novel therapeutics for cancer patients failing standards of care.

Dr Tan continues to be an active practitioner while publishing research impacting the international community. His expertise in lymphoma and multiple myeloma was acknowledged by the publication of two lead-author review articles on their respective treatment guidelines in Lancet Oncology in 2014.  His research has also led to numerous international presentations and more than 100 publications in high impact factor scientific journals including several first-authored articles in the Lancet Oncology, Blood and the Annals of Oncology.

Dr Tan served as the clinical lead for the lymphoma and multiple myeloma services at the Singapore General Hospital and spearheaded several clinical trials examining novel approaches in treating lymphoma and multiple myeloma. He was Assistant Professor at the Duke-NUS Graduate Medical School and received numerous grants from the National Medical Research Council, Singapore Health Foundation and the Singapore Cancer Syndicate for his research.

At Clinic for Lymphoma, Myeloma and Blood Disorders, we are dedicated to providing high-quality, personalized medical care with the most current approaches available.

Core Services

Blood Cancer/ Haemato-Oncology

  • Treatment of lymphoma, multiple myeloma, acute and chronic leukaemias, myelodysplastic syndromes, myeloproliferative neoplasms and other blood cancers
  • Diagnosis, staging, risk stratification and therapy of blood cancers including inpatient and outpatient chemotherapy, immunotherapy and counselling on clinical trials locally and internationally.

Clotting disorders

  • Administration and monitoring of blood thinning medicine (anticoagulation) in the treatment of blood clots like deep vein thrombosis and pulmonary embolism. 
  • Reversal of anticoagulation in the event of severe bleeding.
  • Advice for patients on anticoagulation undergoing surgical and dental procedures

Bleeding disorders

  • Diagnosis of bleeding disorders like immune thrombocytopenic purpura (ITP), haemophilia and von Willebrand disease.
  • Administration of necessary blood products for treatment and prevention of bleeding. 

General Haematology

  • Diagnosis and treatment of anaemia (low red blood cells), thrombocytopenia (low platelets) and leucopenia (low white blood cells).
  • Treatment of autoimmune conditions causing low platelets or haemolytic anaemia with steroids and immunosuppression agents. 
  • Diagnosis and treatment of bone marrow failure syndromes
  • Transfusion of red blood cells and other blood products.
  • Infusion of immunoglobulins for patients with immunodeficiencies.

More than a Clinical Practitioner


In addition to his clinical practice, Dr Tan is deeply involved in teaching and training of young haematologists. His appointment in the Residency Advisory Committee and continued affiliation with the academic hospitals allows him to contribute to post-graduate teaching, and to advise patients on participation in clinical trials for lymphoma and multiple myeloma.


Dr Tan is passionate about providing care for his patients. In recognition of his commitment to patient care, he received the Singapore Health Service Quality Service Gold Award in 2011, long service awards from the Singapore General Hospital and Raffles Hospital in 2008 and 2017 respectively, and the Courage Medal during the Singapore SARS epidemic in 2003. Dr Tan was a Major with the Singapore Armed Forces while serving national service. He held key appointments in the combat support hospital and volunteered for humanitarian missions to disaster areas in the region.

International Experience

Dr Tan was elected into the International Myeloma Working Group in 2014 and also sits on the advisory panel of the International Myeloma Foundation’s Asia Myeloma Network. He is also a member of the Asia Lymphoma Study Group, the American Society of Haematology and the American Society of Clinical Oncology.  He has delivered more than 100 invited lectures on the treatment of lymphoma and multiple myeloma at international conferences and serves as an advisor to many expert panels on novel drugs development. He has led an international phase II study on novel treatment for T-cell lymphoma and the results are published in the Lancet Haematology. He is on the editorial board of several international peer reviewed scientific journals. Dr Tan’s work on immunotherapy in NK/T-cell lymphoma has led to its endorsement on the American NCCN cancer treatment guidelines in 2018. His scientific publications can be found here.

Featured Media Articles

Contact Form

Where are We?

Clinic for Lymphoma, Myeloma and Blood Disorders

Clinic for Lymphoma, Myeloma and Blood Disorders